GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $5.15 Average PT from Analysts

by · The Cerbat Gem

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) has received an average recommendation of “Hold” from the fourteen ratings firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $5.1458.

A number of research firms recently commented on GDRX. TD Cowen decreased their price target on GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Morgan Stanley reduced their price objective on GoodRx from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th. JPMorgan Chase & Co. decreased their target price on GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Mizuho cut their price target on GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Thursday, November 6th. Finally, UBS Group decreased their price objective on shares of GoodRx from $4.25 to $4.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th.

Check Out Our Latest Stock Report on GDRX

Insider Activity

In other news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $4.00, for a total transaction of $95,084.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Invesco Ltd. boosted its position in GoodRx by 91.8% in the 1st quarter. Invesco Ltd. now owns 66,076 shares of the company’s stock valued at $291,000 after buying an additional 31,617 shares during the last quarter. Raymond James Financial Inc. boosted its holdings in GoodRx by 54.6% in the first quarter. Raymond James Financial Inc. now owns 830,950 shares of the company’s stock valued at $3,664,000 after acquiring an additional 293,420 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in GoodRx by 20,956.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 14,529 shares of the company’s stock valued at $64,000 after acquiring an additional 14,460 shares during the last quarter. Jump Financial LLC acquired a new stake in GoodRx in the first quarter worth about $49,000. Finally, Cubist Systematic Strategies LLC raised its holdings in GoodRx by 146.6% during the 1st quarter. Cubist Systematic Strategies LLC now owns 375,648 shares of the company’s stock worth $1,657,000 after purchasing an additional 223,336 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Trading Up 1.5%

Shares of GoodRx stock opened at $2.75 on Thursday. GoodRx has a 12-month low of $2.61 and a 12-month high of $5.81. The stock has a market capitalization of $933.43 million, a P/E ratio of 30.56, a price-to-earnings-growth ratio of 1.03 and a beta of 1.45. The company has a 50-day simple moving average of $2.91 and a 200 day simple moving average of $3.88. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81.

GoodRx (NASDAQ:GDRX – Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $196.03 million during the quarter, compared to analyst estimates of $195.17 million. GoodRx had a net margin of 3.97% and a return on equity of 9.73%. GoodRx’s quarterly revenue was up .4% on a year-over-year basis. During the same quarter last year, the firm earned $0.08 earnings per share. Research analysts expect that GoodRx will post 0.13 earnings per share for the current fiscal year.

About GoodRx

(Get Free Report)

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

Featured Stories